Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2,518

Pollutants, pathogens could team up to make us sick

Imagine that… The earth is round.

Many people view pollutants and pathogens as separate causes of illness. However, recent research indicates that the two can interact, changing how people and animals respond to infectious diseases. According to an article in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, environmental pollutants appear to weaken the immune system, reduce vaccine efficacy and increase pathogen virulence.

More than 20 years ago, researchers showed that exposing mice to low levels of a dioxin called 2,3,7,8-tetrachlorodibenzo–p-dioxin made them more susceptible to influenza virus. Since then, several studies have suggested that other chemicals, such as perfluorooctanoic acid, mercury and arsenic, can also alter animals’ immune responses and decrease their resistance to infectious diseases. And epidemiological studies in humans have linked chemical exposure in the womb to a child’s increased risk of infectious disease. However, scientists are only now beginning to unravel how this happens, Senior Editor Britt Erickson writes.

Compounds called per- and polyfluoroalkyl substances (PFAS) are widely used in household products, such as food packaging, nonstick products and cleaners. Researchers have linked elevated concentrations of some PFAS in mothers’ blood to reduced responses to vaccinations and more illnesses in their children. Similarly, arsenic exposure in the womb has been associated with decreased levels of antibodies against diphtheria in vaccinated Bangladeshi children. Evidence also suggests that some chemicals, such as zinc or lead, may contribute to the rise of multidrug-resistant strains of methicillin-resistant Staphylococcus aureus (known as MRSA). Such interactions are complex and will require more interdisciplinary research in environmental health and infectious disease, Erickson writes.

Novel research links an aging gut microbiome with heart disease

An intriguing new study, led by scientists from the University of Colorado Boulder, suggests an aging gut microbiome may be somewhat responsible for the degradation in cardiovascular heath that tends to appear as we grow older. The study is yet another addition to the growing body of evidence affirming the role gut bacteria plays in age-related disease.

Fountain of youth for heart health may lie in the gut

“We have long known that oxidative stress and inflammation are involved in making arteries unhealthy over time, but we didn’t know why arteries begin to get inflamed and stressed. Something is triggering this,” Seals said. “We now suspect that, with age, the gut microbiota begins producing toxic molecules, including TMAO, which get into the blood stream, cause inflammation and oxidative stress and damage tissue.”

As our collection of resident gut bacteria changes with age, it increasingly produces harmful metabolites that damage veins and blood vessels, driving disease, a new study suggests.

ResTORbio Announces Phase 3 Human Trials

Last year, resTORbio announced the positive results of its phase 2b human trial, which targeted the aging immune system with an immune system-boosting drug. Now, the company has announced the news that its therapy is moving to a phase 3 study later this year after successful negotiation with the FDA.

Targeting the mTOR pathway of aging

ResTORbio is a biopharmaceutical company that is developing therapies that directly target the aging processes in order to prevent or cure age-related diseases. Its primary candidate drug is RTB101, which targets part of the mTOR pathway, one of the pathways involved in aging.

/* */